Insights
Insights From Our Experts
Articles
Successful Early-Stage Out-Licensing Requirements
The attention on vaccines during the COVID-19 crisis highlighted the role of biotech companies and positive sentiment increased for the sector. In 2021, a record number of biotech (100+) companies went public and listed companies soared…
EVERSANA’s Value & Evidence Team’s Work Tops List of Most Read Articles in 2021 in Journal of Comparative Effectiveness Research
If you work in the field of Health Economics and Outcome Research (HEOR) in the life sciences industry, you know just how valuable the Journal of Comparative Effectiveness Research (JCER) is. The publication features peer-reviewed studies…
Social Determinants of Health – What Pharma Can Do!
The US Department of Health and Human Services defines Social Determinants of Health (SDoH) as conditions in the places where people live, learn, work, and play that affect a wide range of health risks and outcomes.1…
Case Study: Leveraging machine learning models in patient identification and behavior prediction for rare disease indications
When a mid-sized pharmaceutical company was challenged with trial and adoption of their immune thrombocytopenia (ITP) drug due to fierce competition and the lingering impact of COVID-19, they turned to the team of data and analytics…
Three Keys to Value for Unlocking the Promise of Cell Therapies
The cell therapy market continues to grow. Estimated at $101 billion in 2021, the global cell therapy market is projected to reach $247 billion by 2028, a CAGR of 13.64%.1 The revenue generation is being driven…
How to Ensure Speed and Efficiency When Launching in Canada
Today is an extraordinary time for medical innovation. The pharmaceutical industry is yielding protection against diseases, focusing more on rare and complex disease treatments, and the world is getting better health outcomes. Global life expectancy is…